NO20021937L - Fremgangsmåte for administrering av en fosfodiesterase 4- hemmer - Google Patents

Fremgangsmåte for administrering av en fosfodiesterase 4- hemmer

Info

Publication number
NO20021937L
NO20021937L NO20021937A NO20021937A NO20021937L NO 20021937 L NO20021937 L NO 20021937L NO 20021937 A NO20021937 A NO 20021937A NO 20021937 A NO20021937 A NO 20021937A NO 20021937 L NO20021937 L NO 20021937L
Authority
NO
Norway
Prior art keywords
phosphodiesterase
administering
inhibitor
Prior art date
Application number
NO20021937A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021937D0 (no
Inventor
Robert D Murdoch
Theodore J Torphy
Barry D Zussman
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20021937D0 publication Critical patent/NO20021937D0/no
Publication of NO20021937L publication Critical patent/NO20021937L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20021937A 1999-10-29 2002-04-24 Fremgangsmåte for administrering av en fosfodiesterase 4- hemmer NO20021937L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16247799P 1999-10-29 1999-10-29
US16264199P 1999-11-01 1999-11-01
US17981700P 2000-02-02 2000-02-02
PCT/US2000/029453 WO2001032165A1 (fr) 1999-10-29 2000-10-26 Procede d'administration d'un inhibiteur phosphodiesterase 4

Publications (2)

Publication Number Publication Date
NO20021937D0 NO20021937D0 (no) 2002-04-24
NO20021937L true NO20021937L (no) 2002-05-30

Family

ID=27388757

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021937A NO20021937L (no) 1999-10-29 2002-04-24 Fremgangsmåte for administrering av en fosfodiesterase 4- hemmer

Country Status (29)

Country Link
US (1) US20030212112A1 (fr)
EP (1) EP1225884A4 (fr)
JP (1) JP2003513038A (fr)
KR (1) KR20020050249A (fr)
CN (1) CN1387433A (fr)
AP (1) AP2002002446A0 (fr)
AR (1) AR026254A1 (fr)
AU (1) AU772909B2 (fr)
BG (1) BG106623A (fr)
BR (1) BR0015039A (fr)
CA (1) CA2389293A1 (fr)
CO (1) CO5271676A1 (fr)
CZ (1) CZ20021443A3 (fr)
DZ (1) DZ3249A1 (fr)
EA (1) EA200200502A1 (fr)
HK (1) HK1049105A1 (fr)
HU (1) HUP0203682A3 (fr)
IL (1) IL148813A0 (fr)
MA (1) MA25562A1 (fr)
MX (1) MXPA02004220A (fr)
NO (1) NO20021937L (fr)
NZ (1) NZ518002A (fr)
OA (1) OA12078A (fr)
PE (1) PE20011004A1 (fr)
PL (1) PL355262A1 (fr)
SK (1) SK7292002A3 (fr)
TR (1) TR200201150T2 (fr)
UY (1) UY26422A1 (fr)
WO (1) WO2001032165A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
AU2003232828B2 (en) * 2002-05-28 2010-06-24 Takeda Gmbh Topically applicable pharmaceutical preparation
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
ME00524B (me) 2003-03-10 2011-10-10 Astrazeneca Ab Novi postupak za dobijanje roflumilasta
TW200420554A (en) * 2003-03-31 2004-10-16 Kyowa Hakko Kogyo Kk A intra-airway administrating preparation
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
JP5383183B2 (ja) 2005-03-16 2014-01-08 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング ロフルミラストを含有する矯味された剤形
MX2012006265A (es) * 2009-12-03 2012-07-25 Opko Health Inc Formulaciones disacaridas hipersulfatadas.
CA2861594A1 (fr) * 2011-12-27 2013-07-04 Celgene Corporation Formulations de (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione
CN103536582A (zh) * 2013-10-12 2014-01-29 云南龙海天然植物药业有限公司 罗氟司特干粉吸入剂
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
MY121142A (en) * 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

Also Published As

Publication number Publication date
PE20011004A1 (es) 2001-09-28
TR200201150T2 (tr) 2002-09-23
EP1225884A1 (fr) 2002-07-31
IL148813A0 (en) 2002-09-12
OA12078A (en) 2003-05-28
AU1344501A (en) 2001-05-14
NO20021937D0 (no) 2002-04-24
EA200200502A1 (ru) 2002-10-31
AU772909B2 (en) 2004-05-13
CZ20021443A3 (cs) 2003-01-15
BR0015039A (pt) 2002-06-25
HK1049105A1 (zh) 2003-05-02
CA2389293A1 (fr) 2001-05-10
UY26422A1 (es) 2001-07-31
BG106623A (bg) 2003-02-28
KR20020050249A (ko) 2002-06-26
HUP0203682A2 (hu) 2003-04-28
JP2003513038A (ja) 2003-04-08
DZ3249A1 (fr) 2001-05-10
SK7292002A3 (en) 2002-12-03
EP1225884A4 (fr) 2005-06-15
AP2002002446A0 (en) 2002-03-31
WO2001032165A1 (fr) 2001-05-10
CN1387433A (zh) 2002-12-25
HUP0203682A3 (en) 2003-10-28
CO5271676A1 (es) 2003-04-30
MA25562A1 (fr) 2002-10-01
PL355262A1 (en) 2004-04-05
NZ518002A (en) 2004-01-30
MXPA02004220A (es) 2002-10-17
AR026254A1 (es) 2003-02-05
US20030212112A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
EE9900517A (et) Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südameveresoonkonna haiguste ärahoidmiseks
IS5739A (is) Efnasambönd óstöðugra DP IV-lata
ATE216997T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ATE230275T1 (de) Angiogense-inhibitor
NO20021937D0 (no) Fremgangsmåte for administrering av en fosfodiesterase 4- hemmer
EE03768B1 (et) Meetod bensimidasoolühendi sünteesiks
PL329153A1 (en) Derivatives of pyrrolopyrolone as inhibitors of neutropil elastase
AU2274299A (en) Benzazine derivatives phosphodiesterase 4 inhibitors
NO20010331L (no) Ftalazinderivater som fosfodiesterase 4-inhibitorer
HUP0105011A3 (en) Synthesis method of nitroxymethylphenyl esters of aspirin derivatives
EE200100383A (et) L-fenüülefriinvesinikkloriidi valmistamise meetod
NO20010298D0 (no) Polymorf av et formakum
IL139450A0 (en) Methods of administering apo b-secretion/mtp inhibitors
NO20004288D0 (no) FremgangsmÕte til fremstilling av et beskyttet 4-aminometyl- pyrrolidin-3-on
NO20012976D0 (no) Anvendelse av inhibitorer av KQTI-kanalen for fremstilling av et medikament
NO20010953L (no) En fremgangsmåte for behandling av stafylokokkal sykdom
IL141446A0 (en) Benzazine derivatives as phosphodiesterase 4 inhibitors
NO20002174D0 (no) FremgangsmÕte for fremstilling av tiazolidindion-derivater
EP1292305A4 (fr) Procede d'inhibition de dopamine utilisant du l-threo-methylphenidate
NO994049D0 (no) Metode for å fremstille farmasöytiske forbindelser
GB0111594D0 (en) Pipecolnic acid derivatives method of manufacturing the same and therapeutic agents containing these compounds
HUP0002083A3 (en) Synthesis of acridine derivative multidrug-resistant inhibitors
EE200100084A (xx) NOS inhibiitorite uued farmatseutilised kasutusv�imalused
NO20021028D0 (no) Fremgangsmåte for overflatemodifisering av en medisinsk slange
PL352374A1 (en) Inhibitors of integrine o v beta 6

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application